natgillin/translations-raw huggingface dataset:
iii) the Fc domain is a human Fc domain; and/or iv) the Fc domain comprises a modification promoting the association of the first and the second subunit of the Fc domain, wherein optionally in the CH3 domain of the first subunit of the Fc domain an amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby generating a protuberance within the CH3 domain of the first subunit which is positionable in a cavity within the CH3 domain of the second subunit, and in the CH3 domain of the second subunit of the Fc domain an amino acid residue is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity within the CH3 domain of the second subunit within which the protuberance within the CH3 domain of the first subunit is positionable. 
iii) Fc domena je ljudska Fc domena; i/ili iv) Fc domena obuhvaća modifikaciju koja potiče udruživanje prve i druge podjedinice Fc domene, pri čemu prema izboru u CH3 domeni prve podjedinice Fc domene aminokiselinski ostatak je zamijenjen aminokiselinskim ostatkom koji ima veći volumen bočnog lanca, čime se stvara izbočina unutar CH3 domene prve podjedinice, koja se može postaviti u šupljinu unutar CH3 domene druge podjedinice, i u CH3 domeni druge podjedinice Fc domene, aminokiselinski ostatak je zamijenjen aminokiselinskim ostatkom koji ima manji volumen bočnog lanca, čime se stvara šupljina unutar CH3 domene druge podjedinice, unutar koje se može postaviti izbočina unutar CH3 domene prve podjedinice.
R1, R2 and R3 may be H; and R4 and R6 may be independently selected from hydrogen, halo, methyl and -C(O)CH3. 
R* je odabran od sljedećih: vodik, halogen i -C(O)R'", pri čemu R'*je metil; i R/ je odabran od sljedećih: vodik, halogen, cijano, metil i trifluorometil.
The method according to claim 3 or claim 4, wherein the drain layer (30) is composed of gravels, or sand, or a combination of both, or a sand-based gradation material. 
Postupak u skladu s patentnim zahtjevom 3 ili patentnim zahtjevom 4, naznačen time što se odvodni sloj (30) sastoji od šljunka ili pijeska, ili njihove kombinacije, ili gradacijski materijal na bazi pijeska.
has a lower specific gravity compared to the fixative (3), and 
ima manju specifičnu gustoću u usporedbi s fiksativom (3), i -
(2003) Vaccine 21:2830-6 . A sterile vaccine comprising an inactivated influenza virus antigen, wherein the vaccine contains no mercurial preservative, no antibiotic, no formaldehyde and no egg-derived materials. 
Sterilno cjepivo koje sadrži inaktivirani antigen virusa influence, naznačeno time da cjepivo ne sadrži konzervanse sa živom, ne sadrži antibiotik, ne sadrži formaldehid 1 ne sadrži materijale dobivene od jaja.
When the reflux disease treatment device 10 is generally spherical, whereby it can be made to wholly or partly encompass the esophagus, the inner diameter D of the reflux disease treatment device 10, is preferably such that it can encompass the esophagus and at least a part of the fundus so that the device does not rest directly against the wall of the esophagus when implanted. The movement restriction device 10 may take any form that enables the device 10 to rest in a position in which movement of the cardiac notch of the patient's stomach towards the patient's diaphragm is restricted, thereby the cardia is prevented from sliding through the patient's diaphragm opening into the patient's thorax and the supporting pressure against the patient's cardia sphincter muscle exerted from the patient's abdomen is maintained. 
452), koji je u fluidnoj komunikaciji s komorom proširljivog tijela, gdje se uređajem za rukovanje može neinvazivno rukovati radi distribuiranja fluida iz spremnika fluida u komoru proširljivog tijela kako bi se proširilo tijelo, tako da se dio stijenke želuca rastegne kada je proširljivo tijelo invaginirano. Uređaj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što je uređaj prilagođen da bude u najmanju ruku djelomično invaginiran u stijenku želuca međuželučanim kopčama, s vanjske strane stijenke želuca. Uređaj u skladu s patentnim zahtjevom 6, naznačen time što je spremnik fluida (452) prilagođen za rukovanje ručnim pritiskanjem spremnika fluida.
The pharmaceutical composition of any of claims 3 to 4, for use in the manufacture of a medicament for treating or preventing a disorder or disease associated with an RyR that regulates calcium channel functioning in cells. The pharmaceutical composition of claim 5, wherein the disorder or disease is selected from the group consisting of cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. 
C 2 (536), za liječenje ili prevenciju poremećaja ili bolesti povezanih s RyR koji regulira funkciju kalcijevih kanala u stanicama, ili u proizvodnji lijeka za takvo liječenje ili prevenciju, pri čemu je poremećaj ili bolest povezana s RyR izabrana iz grupe koju čine poremećaji i bolesti skeletnih mišića, kognitivni poremećaji 1 bolesti, maligna hipertermija, dijabetes i sindrom iznenadne smrti novorođenčeta.
The method according to any one of claim 1 to 17 and 19 to 21, characterized in that the method is suited for the production of a secreted heterologous immunoglobulin in large scale. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 17 1 19 do 21, naznačen time, da je postupak pogodan za proizvodnju izlučenog heterolognog imunoglobulina u velikom opsegu.
An immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid which is pneumolysin, diphtheria toxoid or CRM197 and 19F is conjugated to a second bacterial toxoid which is diphtheria toxoid or CRM197 and further comprising conjugates of S. pneumoniae capsular saccharides 4, 6B, 9V, 14, 18C, 23F, 1, 5 and 7F, wherein the average size of the 19A saccharide is between 110 and 700 kDa. 
Imunogeni pripravak, naznačen time što sadrži konjugate saharida iz kapsule bakterije S. pneumonijae iz serotipova 19A i 19F, gdje je 19A konjugiran s prvim bakterijskim toksoidom, koji je pneumolizin, difterijski toksoid ili CRM197, a 19F je konjugiran s drugim bakterijskim toksoidom, koji je difterijski toksoid ili CRM197, te što dodatno sadrži konjugate saharida 4, 6B, 9V, 14, 18C, 23F, 1, 5 i 7F iz kapsule bakterije S. pneumonijae, gdje je prosječna veličina saharida 19A između 110 i 700 kDa.
A neutralizing anti-NR10/IL-31RA antibody that recognizes the region of amino acids between positions 21 and 120 in the amino acid sequence of human NR10/IL-31RA of SEQ ID NO: 76, wherein the antibody comprises the heavy chain variable region of SEQ ID NO: 12 and the light chain variable region of SEQ ID NO: 16. 
protutijelo koje sadržava varijabilne regije teških lanaca sa sekvencama CDR1 od SEQ ID NO: 9, CDR2 od SEQ ID NO: 197 i CDR3 od SEQ ID NO: 184 (H30, H44) i varijabilnu regiju lakog lanca koja sadržava CDR1 od SEQ ID NO: 202, CDR2 od SEQ ID NO: 170 i CDR3 od SEQ ID NO: 193 (L17);
The use of any of claims 16-19, together with a second therapeutic agent useful in the treatment or prevention of a disease or condition selected from emotional lability; pseudobulbar affect; autism; neurological disorders; neurodegenerative diseases; brain injury; disturbances of consciousness disorders; cardiovascular diseases; glaucoma; tardive dyskinesia; diabetic neuropathy; retinopathic diseases; diseases or disorders caused by homocysteine-induced apoptosis; diseases or disorders caused by elevated levels of homocysteine; chronic pain; intractable pain; neuropathic pain; sympathetically mediated pain; pain associated with gastrointestinal dysfunction; epileptic seizures; tinnitus; sexual dysfunction; intractable coughing; dermatitis; addiction disorders; Rett syndrome (RTT); voice disorders due to uncontrolled laryngeal muscle spasms; methotrexate neurotoxicity; and fatigue caused by cancer. 
Uporaba iz bilo kojeg od patentnih zahtjeva 19-21, zajedno s drugim terapijskim agensom korisnim u liječenju ili prevenciji bolesti ili stanja odabranih između emocionalne labilnosti; pseudobulbarnog afekta; autizma; neuroloških poremećaja; neurodegenerativnih bolesti; ozljeda mozga; poremećaja narušavanja svijesti; kardiovaskularnih poremećaja; glaukoma; tardivne diskinezije; dijabetičke neuropatije; retinopatskih bolesti; bolesti ili poremećaja uzrokovanih homocisteinom induciranom apoptozom; bolesti ili poremećaja uzrokovanih povećanom razinom homocistemna; kronične boli; tvrdokorne boli; neuropatske boli; simpatički posredovane boli; boli povezane s gastrointestinalnom disfunkcijom; epileptičkih napada; tinitusa; seksualne disfunkcije; tvrdokornog kašlja; dermatitisa; poremećaja ovisnosti; Rett sindroma (RTT); poremećaja glasa zbog nekontroliranog spazma mišića larinksa; neurotoksičnosti metotreksata; i umora uzrokovanog karcinomom.
It is also disclosed that the light stream after draining has a free liquid and the percent amount of the free liquid by weight on wet basis in the light stream after draining may be less than a value selected from the group consisting of 20%, 10% and 5% of the light stream. 
Proces iz patentnog zahtjeva 5, gdje lagani tok poslije dreniranja ima slobodnu tekućinu i postotna količina slobodne tekućine po masi na vlažnoj osnovi u laganom toku poslije dreniranja je manja od vrijednosti odabrane iz grupe koja se sastoji od 20%, 10% i 5% laganog toka.
The method of claim 16, wherein the retinal neurodegenerative disease is diabetic retinopathy. The method of claim 16, wherein the subject is a human. 
Farmaceutski topikalni pripravak, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 13-16, naznačen time što je neurodegenerativna bolest mrežnice dijabetična retinopatija.
A compound represented by the following general formula (IB) or a pharmacologically acceptable salt thereof: [wherein R1 represents a hydrogen atom or a C1-C3 alkyl group; R5 represents a group selected from substituent group a; 
[image] gdje R1 predstavlja atom vodika ili C1-C3 alkil grupu; R5 predstavlja grupu izabranu od grupe supstituenta a; i grupa supstituent a je kao što je definirana u patentnom zahtjevu 1.
Compositions according to claim 1 or 2 wherein the ginseng extract has a ginsenoside content of 8% with a ginsenoside Rgl/ginsenoside Rb1 ratio of 0.5/1, the Zingiber officinale extract has a gingerol content of 30% and the Echinacea angustifolia extract has an isobutylamide content higher than 20% by weight. 
Pripravci prema patentnom zahtjevu 1 ili 2, naznačeni time da je u ekstraktu ginsenga sadržaj ginsenozida 8%, a omjer ginsenozida Rgl/ginsenozida Rb1 jest 0.5/1, da je u ekstraktu Zingiber officinale sadržaj gingerola 30% te da je u ekstraktu Echinacea angustifolia sadržaj izobutilamida veći od 20% po masi.
The aqueous phase was washed with dichloromethane (3x150 mL) then the organic phases combined, washed with brine (150 mL), dried (sodium sulfate) and the solvent evaporated. 
Vodenu fazu ispere se diklormetanom (3 x 150 ml), organske faze pomiješa, ispere slanom vodom (150 ml), osuši (natrijev sulfat), a otapalo otpari.
While the small intestine is assigned to the digestion of the majority of the food, to the absorption thereof, to the production of B-complex vitamins and vitamin K, to the metabolism of biliary acids and various other organic substances and to the rapid transfer of the alimentary bolus to the sections further downstream, the large intestine provides for the absorption of water, for the digestion of vegetable fibres and for the completion of some digestive processes initiated in the small intestine. 
Uloga tankog crijeva uključuje probavu i absorpciju većeg dijela hrane, stvaranje vitamina B-kompleksa i vitamina K, metabolizam žučnih kiselina i različitih drugih organskih tvari te brzi prijenos probavnog sadržaja dalje u nastavak crijeva. Uloga debelog crijeva je absorpcija vode, probava biljnih vlakana te završavanje nekih probavnih procesa započetih u tankom crijevu.
said crane unit is arranged to transfer a load or a group of loads to and from said ship, is supported by said longitudinal rail and is displaceable along said longitudinal rail; 
- < navedena jedinica sa dizalicom izvedena je tako da vrši transport tereta ili skupina tereta na i/ili iz broda, a poduprta je navedenom uzdužnom šinom i može se pomicati uzduž navedene uzdužne šine;
Process in accordance with any preceding claim, in which the melt in the melter comprises a single toroidal flow pattern comprising major centrally inwardly convergent flow vectors at the melt surface, with the central axis of revolution of the toroid being vertical 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što talina u talioniku ima jedan toroidni uzorak tečenja, kojeg čine glavni središnji prema unutra usmjereni konvergentni vektori tečenja na površini taline, gdje je središnja os vrtnje toroida okomica.
The pharmaceutical composition for use according to one of claims 1 to 6, wherein the lubricant is talc, polyethyleneglycol, calcium behenate, calcium stearate, hydrogenated castor oil or megnesium stearate. 
Farmaceutski pripravak sukladno jednom od zahtjeva 1 do 5, naznačeno time da je sredstvo za podmazivanje puder, polietilenglikol, kalcij behenat, kalcij stearat, hidrogenizirano ricinusovo ulje ili magnezij stearat.
The composition according to claim 1, which is a solution in which said polypeptide is present at a concentration in the range of 0.03 to 200 nmol/ml, 0.3 to 200 nmol/ml or 30 to 120 nmol/ml. The composition according to claim 1, which is formulated for oral administration, nasal administration, epicutaneous administration, subcutaneous administration, sublingual administration, intradermal administration, buccal administration or for administration by inhalation or by injection. 
Farmaceutska formulacija, naznačena time, što za uporabu u prevenciji ili liječenju alergije na grinje iz prašine po toleranciji se sastoji od sastava ili vektora u skladu sa bilo kojim zahtjevom 1 do 9; ili proizvoda u skladu sa zahtjevom 10; i farmaceutski prihvatljivih nositelja ili otapala, opcionalno pri čemu je sastav, vektor ili proizvod formuliran za oralnu primjenu, nosnu primjenu, epikutanu primjenu, potkožnu primjenu, sublingvalnu primjenu, intradermalnu primjenu, bukalnu primjenu ili za primjenu udisanjem ili injektiranjem
The method of claim 2 wherein said compound of Formula II, or pharmaceutically acceptable salt form thereof, is administered in the form of a transdermal patch, ointment, lotion, cream, or gel. 
Spoj za uporabu prema zahtjevu 6, naznačen time da je navedeni spoj za davanje u obliku transdermalnog flastera, masti, losiona, kreme ili gela.
A dispenser according to claim 1 or claim 2, wherein the cam follower comprises two substantially rigid protrusions (18a, 18b) extending from the base, and the junction member sits atop the upper surface of the protrusions. 
Dispenzer sukladno zahtjevu 1 ili zahtjevu 2, naznačen time da se pratitelj brega sastoji od dva znatno rigidna izbočenja (184), (18b) koja se protežu od baze, 1 da spojni dio leži povrh gornje površine izbočenja.
The system of claim 1, further comprising an additional sensor configured to monitor a battery voltage of a battery coupled to the flush valve. The system of claim 1, further comprising an additional sensor configured to monitor the number of times the main valve element is transitioned between the first position and the second position which are initiated by manual operation of the operator, and the number of times the main valve element is transitioned from the first position to the second position which are initiated by electronic operation means. 
Sustav u skladu s patentnim zahtjevom 1, naznačen time što dodatno sadrži dodatni senzor, konfiguriran za praćenje napona baterije spojene s elektromagnetskim ventilom (10), broja puta kada glavni ventilni element (300) prelazi između prvog položaja i drugog položaja što ručno pokreće operator, te broja puta kada glavni ventilni element (300) prelazi iz prvog položaja u drugi položaj što pokreće elektronski upravljač, ili kvalitete vode u tekućini koja prolazi kroz elektromagnetski ventil (10).
A process according to claim 1 wherein said fluoroalkyl sulfonic acid ester is the trifluoromethylsulfonic acid ester. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeni ester alkil- ili arilsulfonske kiseline je ester trifluormetilsulfonske kiseline.
After 1 h, the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (3×50 mL). 
Poslije 1 sata, reakcijska smjesa je razrijeđena sa vodom (50 mL) 1 ekstrahirana sa EtOAc (3 X 50 mL).
transmitting a plurality of said characteristic signal patterns at different timings and/or in different portions of the spectrum and/or spread spectrum modulated with different spreading codes; and 
- < za prijenos mnoštva navedenih karakterističnih oblika signala (DEL) u različitim odabirima vremena i/ili u različitim dijelovima spektra i/ili u širokom spektru moduliranom s različitim zaporkama širenja; te
A crystal according to claim 9, which has an X-ray diffraction pattern shown in any one of Figures 1 to 16 in a powder X-ray diffraction diagram obtained by irradiation with copper Ka radiation (wavelength λ = 1.54 A). 
Kristal prema patentnom zahtjevu 9, koji ima obrazac difrakcije X-zraka prikazan na bilo kojoj od Slika 1 do 16 na dijagramu difrakcije X-zraka na prahu dobivenom ozračivanjem Ka radijacijom bakra (valna dužina A = 1.54 A).
The mechanism for absorbing kinetic energy in shock absorbers and barrier ends for roadways, according to claim 1, characterized in that the deformable metallic profile (2) consists of two or more consecutive sections, arranged longitudinally one after the other, which can, with respect to each other, have a different dimension for one or more of the parts or faces forming their cross-section, or have different thickness. 
Sustav u skladu s patentnim zahtjevom 1, naznačen time što je deformabilni profil (2) sa svoje strane načinjen od dva ili više uzastopnih odjeljaka (2) (2"), smještenih uzdužno jedan za drugim, koji mogu, jedan s obzirom na drugi, imati različitu dimenziju jednog ili više dijelova ili strana koje čine njihov poprečni presjek ili imaju različitu debljinu, ili imaju različite dimenzije strana poprečnog presjeka i različitu debljinu.
The process of claim 17 wherein the amount of guar gum is from about 0.1 to 3%. The process of claim 18 comprising about 0.25% to 2.5% guar gum. 
Mrvice prema zahtjevu 15 gdje je količina guar gume od 0.1 do 3%, bolje od 0,25% do 2,5%, još bolje od 0.7% do
The method of claim 1, wherein each of the solid-phase amplification products comprises a binding site for a universal sequencing primer. 
Metoda iz patentnog zahtjeva 2, pri čemu produkti umnožavanja na čvrstoj fazi obuhvaćaju vezno mjesto za univerzalnu početnicu za sekvenciranje.
Vaccine according to any one of claims 1 to 5, characterised in that the at least two fragments of PCSK9 comprise a cysteine residue at the C- and/or N-terminal end. 
Cjepivo prema bilo kojem od zahtjeva 1 do 4, naznačeno time, da najmanje dva fragmenta od PCSK9 sadrže cisteinski ostatak na C-završnom kraju i/ili na N-završnom kraju.
the prevention of reactivation of tuberculosis; or the delay of reactivation of tuberculosis. 
(c) sprječavanju reaktiviranja tuberkuloze; ili (d) odgađanju reaktiviranja tuberkuloze.
The message controller as claimed in claim 1, wherein the fresh response includes data retrieved from a database or from a remote resource server. 
Kontroler poruka prema bilo kojem od prethodnih zahtjeva, pri čemu novo konstruirani odgovor sadrži podatke preuzete iz baze podataka ili od udaljenog resursnog servera.
The sodium salt of (S)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid and solvates thereof, in amorphous form or in the form of a crystalline solvate. 
Natrijeva sol, naznačena time, da je od (S)-2-(difenilacetil)-l,2,3,4-tetrahidro- 6-metoksi-5-(fenilmetoksi)-3-izokinolin-karboksilne kiseline i njezini solvati, pri čemu se nalaze u amorfnom obliku ili u obliku kristalnog solvata.
All data (tumor measurements and animal weights) are captured twice-weekly beginning with the start of therapy and analyzed using a computer based tumor measurement system. 
Podaci (mjerenja tumora 1 težine životinja) uzimani su dvaput tjedno počevši od početka terapije, te analizirani kompjuteriziranim sustavom za mjerenje tumora.
Pharmaceutical compositions according to claims 11 to 15 for use in the treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases. Pharmaceutical compositions for use according to claim 16, characterized in that said tumor diseases include malignant neoplasias and metastasis. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 14 do 16, naznačen time što je namijenjen upotrebi u liječenju prekanceroznih lezija, displazija, metaplazija i tumorskih bolesti, što može uključivati zloćudne novotvorine i metastaze.
The product was dissolved in a concentrated aqueous sodium hydroxide solution (30%) and the resulting solution extracted with a mixture of dichloromethane/methanol/concentrated aqueous ammonia solution in the proportions of 100/0/0 to 70/30/3. 
Produkt se otopi u koncentriranoj vodenoj otopini natrijevog hidroksida (30 %), a dobivenu otopinu ekstrahira smjesom diklormetan/metanol/koncentrirana vodena otopina amonijaka, u odnosima od 100/0/0 do 70/30/3.
The product was obtained by analogy with the method described in example 1 (step 1.7) and using 3-oxo-3-pyrimidin-4-yl-propionic acid methyl ester. 
Produkt se dobije postupkom analognim onom opisanom u primjeru 1 (korak 1.7), uz upotrebu metilnog estera 3-okso-3-pirimidin-4-il-propionske kiseline.
Several publications relates to the use of derivatives of diphenyl sulphides as “radiopharmaceuticals” for imaging SERT by SPECT or PET imaging, e.g. 
Nekoliko publikacija odnosi se na korištenje derivata difenil sulfida kao "radiofarmaceutskih lijekova" za snimanje SERT putem SPECT ili PET snimaka npr.
After 18 hours, the reaction is evaporated and the residue dissolved in water. 
Nakon 18 sati, reakcijsku smjesu se ispari i ostatak se otopi u vodi.
The IC50 values (compound concentration which causes 50% inhibition) for each competing compound are calculated after deduction of non-specific binding (measured in the presence of 10 µM unlabeled ligand). 
Vrijednosti IC5, (koncentracija spoja koja uzrokuje 50 %-tnu inhibiciju) za svaki konkurirajući spoj izračunate su nakon određivanja nespecifičnog vezanja (izmjerenog u prisutnosti 10 uM neobilježenog liganda).
the multispecific antigen-binding molecule of [3], wherein the antigen-binding sites included in the third polypeptide and the fourth polypeptide comprise an antigen-binding site which comprises an L chain variable region consisting of any one of the amino acid sequences selected from the following (c1) to (c10), or an antigen-binding site functionally equivalent thereto: 
(b) mjesta vezanja antigena uključena u treći polipeptid i četvrti polipeptid, obuhvaćaju mjesto vezanja antigena koje obuhvaća varijabilno područje L-lanca koje se sastoji od bilo koje od aminokiselinskih sekvenci odabranih od sljedećih (c1) do (c10):
The process according to claim 7, wherein the step (f) comprises crystallisation using a toluene and isohexane solvent system. 
Postupak prema zahtjevu 7, naznačen time da korak (1) sadrži kristalizaciju uz korištenje sustava otapala toluena i izoheksana. nN=0
After stirring for 30 minutes the resulting suspension is filtered and dried in vacuo at 110° C. to yield the titled product as a yellow solid. 
Nakon miješanja 30 minuta dobivenu suspenziju se profiltrira i osuši u vakuumu pri 110"C, čime se dobije naslovni proizvod kao žuta krutina.
By way of illustration, but not as limitations, embodiments of this invention provide a fill volume of 1 ml for a vial containing 0.25 mg ET-743, and 4 ml for a vial containing 1 mg ET-743. 
Radi ilustracije, ali ne kao ograničenje, varijante ovog izuma osiguravaju zaprem inu punjenja od 1 ml za ampulu koja sadrži 0.25 mg ET-743, i 4 ml za ampulu koja sadrži 1 mg ET-743.